Adaptive Biotechnologies today announced the recent publication of a study in JAMA Oncology that demonstrates that measurement of minimal residual disease (MRD) is a critical tool in evaluating response to new highly effective drug combinations for the treatment of multiple myeloma.
Adaptive Biotechnologies, the leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors, will present data from a study of more than 400 children with acute lymphoblastic leukemia (ALL), some observed for more than a decade, demonstrating that the company’s immunosequencing platform, available clinically in the United States as the clonoSEQ® Process, can more sensitively detect minimal residual disease (MRD) than flow cytometry, and that MRD detected using this method is predictive of a patient’s ultimate outcome. These data and more will be presented at the 20th Congress of the European Hematology Association in Vienna, Austria, June 11-14, 2015.
Adaptive Biotechnologies announced the publication of a joint study with the Children’s Oncology Group (COG) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) demonstrating that minimal residual disease detected using next-generation sequencing (NGS), available clinically as the clonoSEQ® MRD Test through the company’s CLIA-certified laboratory, can more accurately predict relapse and survival compared to multichannel (6-color) flow cytometry in pediatric acute lymphoblastic leukemia (ALL) patients undergoing donor stem cell transplants.
SEATTLE, Wa., May 29, 2015 – Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, and its collaborators will present data demonstrating the utility of immunosequencing from tissue and blood in predicting and monitoring response in cancer at the 2015 American Society of Clinical Oncology® (ASCO®) meeting in Chicago from May 29-June 2, 2015.
SEATTLE, WA – Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors, demonstrated in today’s issue of Nature Medicine the ability of the immunoSEQ® Assay to interrogate cell fate in naturally occurring T-cell populations. Contrary to previous thinking, the results show that different types of T cells often descend from a common ancestor. These findings are a groundbreaking advance in the understanding of adaptive immunity and its potential role in pathogenic response.
SEATTLE, WA – Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, and its collaborators will present data demonstrating how profiling a patient’s T-cell repertoire may lead to diagnostic and therapeutic discovery in immune-mediated diseases at the American Association of Immunologists (AAI) Annual Meeting in New Orleans from May 8-11, 2015.
Adaptive Biotechnologies, a leader and pioneer in next generation sequencing (NGS) of T-cell and B-cell receptors in the immune system, announced today the completion of Adaptive’s Series F financing round with a $195 million investment to support several strategic growth initiatives. This round was led by Matrix Capital Management and included other new investors Senator Investment Group, Tiger Management, Rock Springs Capital and an additional large healthcare investor, alongside participation from existing investors Viking Global, Casdin Capital and Alexandria Real Estate Equities. Adaptive is also backed by industry-leading strategic investors Illumina, Celgene, BD Biosciences and LabCorp.
SEATTLE, WA - Adaptive Biotechnologies today announced the recent publication of a study conducted with researchers at The University of Texas MD Anderson Cancer Center showing that the company’s next-generation sequencing-based approach to identification and quantification of populations of B cells can detect tumor-specific DNA sequences in the blood of people with classical Hodgkin’s lymphoma (CHL).
SEATTLE, WA – Adaptive Biotechnologies today announced the recent publication of a study demonstrating that analysis of circulating tumor DNA (ctDNA) using the company’s next-generation sequencing-based minimal residual disease detection and quantification method (clinically-available as the clonoSEQ™ MRD test) can detect relapse in diffuse large B-cell lymphoma (DLBCL) patients with significantly higher specificity than positron emission tomography combined with CT (PET/CT).
Seattle, WA – Adaptive Biotechnologies, the company pioneering Next Generation Sequencing (NGS) applications for cancer immunology, and its collaborators will present data demonstrating how profiling a patient’s T-cell repertoire may inform clinical care in patients with melanoma and other solid tumors at the American Association for Cancer Research® (AACR) meeting in Philadelphia from April 18-22, 2015.
Le Parker Meridien Hotel
New York, NY
Julie Rubinstein, EVP, Corporate & Business Development, to particpate in panel discussion:
Continued Opportunities in Immuno-Oncology; Exploring Next-Generation Checkpoint Inhibition
Click here for more information.
Sheraton Denver Downtown
11:00 am – 12:30 pm
Immune Therapy and Immune Modulation Workshop:
Trial Design Focus: T-cell Clonality to Predict Patient Responses to Immunotherapy:
Company Perspective - Immunosequencing: Unveiling New Molecular Biomarkers for Immunotherapy.
Presenter: Catherine Sanders, PhD, Adaptive Biotechnologies
4:00 pm – 6:00 pm
Translational Science Lung Cancer Subcommittee:
Immunosequencing: Generating a Potential New Class of Diagnostics
Presenter: Sharon Benzeno, PhD, MBA, Adaptive Biotechnologies
Click here for more information.
Eastern Daylight Time
Since the introduction of antibodies to the treatment of cancer, immunotherapies and targeted therapies have had a dramatic effect on the field. The earliest immunotherapy introduced for the treatment of cancer was humanized-murine antibodies directed against single-cell surface markers present on lymphoma and leukemia cells. While this marked a great advance in the treatment of cancer, innovations have come a long way since then and have helped improve upon nearly every aspect of the discovery, engineering and manufacture of immunotherapies for the treatment of cancer.
Jeremy Graff, Ph.D., Senior Vice President, Biothera Pharmaceutical Research
Björn Frendeus, Ph.D., Chief Scientific Officer, BioInvent
Harlan Robins, Ph.D., Adaptive Biotechnologies
Robert Pierce, M.D., Chief Science Officer, OncoSec
In this webcast we will explore some of the challenges and opportunities of technologies at the cutting edge of cancer immunotherapy. You will learn about new approaches that have been developed to
- Harness the full potential of our immune system.
- Screen for novel target and antibody combinations.
- Enlist our own immune system to attack cancer cells, and
- Improve the delivery of cancer-specific therapeutics to tumors.
The webcast will include a round table discussion on the field and a Q&A section to allow you to participate and contribute your own thoughts on this highly innovative area of cancer research.